# Expression, Distribution and Function of the Transient Receptor Potential Vanilloid Type 1 (TRPV1) in Endometrial Cancer

**Authors:** Thangesweran Ayakannu, Anthony H. Taylor, Justin C. Konje

PMC · DOI: 10.3390/ijms26073104 · International Journal of Molecular Sciences · 2025-03-27

## TL;DR

This study explores how the TRPV1 receptor is involved in endometrial cancer, finding that its reduced expression may contribute to cancer progression.

## Contribution

The study reveals that TRPV1 expression is significantly reduced in endometrial cancer tissues and suggests a pro-apoptotic mechanism independent of TRPV1 activation.

## Key findings

- TRPV1 transcript and protein levels are significantly reduced in endometrial cancer tissues.
- Anandamide, but not capsaicin, reduces Ishikawa cell numbers in vitro.
- Loss of TRPV1 expression is linked to increased proliferation and altered apoptotic markers in EC.

## Abstract

The transient receptor potential vanilloid 1 receptor (TRPV1) is a calcium-sensitive membrane receptor activated by capsaicin and the endocannabinoid, anandamide (AEA). Once activated in vitro, endometrial cancer (EC) cell growth appears to be inhibited through increased apoptosis, but the mechanism remains unclear. Our aim was to investigate the expression and distribution of TRPV1 in normal and cancerous endometria and to determine the precise in vitro mechanism of decreased EC cellular growth. TRPV1 expression in patients with endometrial carcinoma (15 Type 1 EC, six Type 2 EC) and six normal patients (atrophic endometria) was assessed using quantitative RT-PCR and immunohistochemistry (IHC). Additionally, immunohistochemical staining for the proliferation marker Ki-67, the pro-apoptotic marker BAX and the anti-apoptotic marker Bcl-2 were explored. TRPV1 transcript (p = 0.0054) and immunoreactive protein (p < 0.0001) levels were significantly reduced in all EC tissues when compared to control (atrophic) endometria. The almost 50% reduction in TRPV1 transcript levels was mirrored by an almost complete loss of immunoreactive TRPV1 protein. The increased proliferation (Ki-67) of EC tissues correlated with the expression of mutated BAX and inversely correlated to Bcl-2, but only in Type 2 EC samples. In vitro, AEA caused a decrease in Ishikawa cell numbers, whilst capsaicin did not, suggesting the anti-proliferative effect of AEA in EC cells is not via the TRPV1 receptor. In conclusion, the loss of TRPV1 expression in vivo plays a role in the aetiopathogenesis of EC. Activation of cells by AEA also probably promotes EC cell loss through a pro-apoptotic mechanism not involving TRPV1.

## Linked entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Proteins:** TRPV1 (transient receptor potential cation channel subfamily V member 1), Mki67 (antigen identified by monoclonal antibody Ki 67), BAX (BCL2 associated X, apoptosis regulator), BCL2 (BCL2 apoptosis regulator)
- **Chemicals:** capsaicin (PubChem CID 1548943), anandamide (PubChem CID 5281969)
- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}
- **Diseases:** 2 EC (MESH:D016889), atrophic (MESH:D020966)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** EC — Homo sapiens (Human), Type II endometrial adenocarcinoma, Cancer cell line (CVCL_1274), Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11988754/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11988754/full.md

## References

75 references — full list in the complete paper: https://tomesphere.com/paper/PMC11988754/full.md

---
Source: https://tomesphere.com/paper/PMC11988754